摘要
目的 :探讨异丙托溴铵和盐酸氨溴素在慢性阻塞性肺疾病 (COPD)治疗中的作用。方法 :将COPD住院患者 4 7例随机分成两组 ,除常规治疗外 ,第一组 (2 5例 )辅加异丙托溴铵 0 .5mg +生理盐水 3ml雾化吸入 ;第二组 (2 2例 )辅加盐酸氨溴素 15mg +异丙托溴铵 0 .5mg +生理盐水 1ml雾化吸入 ,治疗前及治疗 3d后测定FEV1。结果 :第二组治疗提升FEV1的作用显著强于第一组 (P <0 .0 5 ) ,并使平均住院日显著缩短 (P <0 .0 5 )。结论 :盐酸氨溴素与异丙托溴铵联合雾化吸入治疗COPD具有协同作用 ,优于单一异丙托溴铵。
Objective:To study the role of Ipratropium Bromide and Ambroxol Hydrochoride in the treatment of chronic obstructive pulmonary disease(COPD).Methods:47 cases of male patients with COPD (exacerbation phrase)were grouped randomly. Except for ordinary treatment, Group 1 patients (25 cases)were treated with nebulizing inhalation of Ipratropium Bromide(Atrovent),group 2 patients(22 cases)were treated with nebulizing inhalation of Ipratropium Bromide and Ambroxol Hydrochoride(Mucosolvan). Results:Group 2 patients had significantly higher increasement of FEV 1 and significantly shorter average hospitalizing days than group 1 patients.Conclusions:Combined use of Ipratropium Bromide and Ambroxol Hydrochoride has synergistic action for the treatment of COPD.
出处
《中国现代医学杂志》
CAS
CSCD
2002年第19期46-47,共2页
China Journal of Modern Medicine
